UPDATE: Emerging Treatments in Fight Against COVID-19 .

COVID-19 research continues to expand rapidly, with hundreds of new interventional trials and many fresh treatment combinations entering the pipeline. Convalescent plasma has gained momentum, while interest in antivirals like lopinavir–ritonavir and remdesivir has cooled somewhat, and favipiravir has seen a noticeable rise. Meanwhile, long-standing favourites—hydroxychloroquine, stem cells, and tocilizumab—remain common across registries. A handful of RCTs have begun to report results, prompting cautious updates from major health agencies, yet most treatments still lack convincing evidence. Across guidelines, the message remains clear: outside research settings, routine use of these therapies is not supported, and high-quality trials are still urgently needed.